MARKETS / NASDAQ / FEED
NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · SMALL CAP

ENvue Medical, Inc. FEED

12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.6M
▼ 0.2% vs FY2024
EPS · FY25
$-26.69
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-106.6%
Net margin · FY25
-712.3%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.6M
Revenue, FY2025 · full 12-year series below
Revenue Net income
0.00080.00160.00240.00320.0-0.020142017202020232025
0.00080.00160.00240.00320.0-0.02016201920222025

The company lost 712 cents on every revenue dollar this year.

Per share
USD -26.69
Diluted EPS, FY2025
EPS
0.40.81.2-26.6920142017202020232025
0.40.81.2-26.692016201920222025

The company pays no cash dividend.

Profitability
-106.6%
Return on equity, FY2025
ROE
0.250.50.751-106.6%20142017202020232025
0.250.50.751-106.6%2016201920222025
Operating margin-896.6%
Net margin-712.3%
Return on assets-81.3%

Each USD of equity lost 107 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+32.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+50.3%
+32.6%
+33.0%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.00B
Shares outstanding, FY2025
0.000.0020142017202020232025
0.000.002016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 41.1M
total assets, end of FY2025
Total assetsUSD 41.1M
EquityUSD 33.5M
CashUSD 4.2M
Current ratio1.09×

Equity funds 81% of total assets.

History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−26.69
−137.30
−23.32
−3.84
−0.57
−0.42
−0.83
−0.64
−1.17
−0.62
−0.82
−17.08
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−106.6
−160.5
−102.8
−114.1
−328.1
−231.3
−640.2
−202.8
−874.9
·
·
·
Shares out B
0.00
0.00
0.00
0.00
0.00
0.02
0.00
0.00
0.00
0.00
0.00
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed